Based on mRNA analysis, the test demonstrates high accuracy and could become an important tool for early screening of heart diseases. The key to the new test was the S100A7 protein, the level of which is significantly elevated in patients with acute heart failure—almost twice as high as in healthy individuals. When comparing data from healthy volunteers and patients, the accuracy reached 82 percent, which is significantly higher than traditional tests based on direct measurement of the protein, where the indicators ranged around 52 percent. If the results are confirmed in larger cohorts, the saliva-based test could become the first truly widely available method for heart failure screening.
About the Author
